

Table 1. Characteristics of studies reported SCD children infected with SARS-CoV-2.

Sample size /Mean age/Hb F%	SCD genotype/ HU treatment (%)	ICU admission-death/overall COVID-19 outcome	Reference
7/14.3 years/-one patient	6 SS, one SC/4 on HU therapy	one ICU admitted/all recovered	5
1/2-year 9-month/Not reported	SS/on HU therapy	-/Asymptomatic during hospitalization/recovered	7
1/6-month/Not reported	SC/Not reported	No ICU admission/recovered	6
8/ 16 years/Not reported	SS/ those without ACS were on HU therapy	No ICU admission/ all recovered	8
44/<19 years	SS/ S β^0 , SC/S β^+ /Not reported	1 death (2.3%)	9
4/children/Not reported	Not reported	0%-no death/recovered	10
4/14.5 years/12.3%	SS/ 50% on HU therapy	4 patients-no death/recovered	11
1/16 years/Not reported	SS/on HU therapy	-ICU admitted-no death/recovered	12
2/13 years/ Not reported	SS/one on HU therapy	No ICU admission/ both recovered	26
10 /<20 years/ Not reported	Not reported	Not reported- one death at age group>10 years	13
186<19 years/Not reported	Not reported	-/one death (0.5%)	14

SCD: Sickle cell disease; HU: hydroxyurea; COVID-19: Coronavirus disease 2019 (COVID-19); ICU: Intensive care unit; SS: sickle cell homozygous

Table 2. Characteristics of studies reported SCD adults infected with SARS-CoV-2.

Sample size /Mean age/Hb F%	SCD genotype/ HU treatment (%)	ICU admission-death/overall COVID-19 outcome	Reference
134≥19 years	SS/ Sβ ⁰ , SC/Sβ ⁺ /Not reported	12 death (9%)	9
24/52.9/ Not reported	4 SS, 1 SC, 1 S/β ⁰ -thalassemia, 18 AS/ 0%	No ICU admission in SCD, 1 AS death	15
1/21 years/ Not reported	HbS/β ⁰ -thalassemia/on HU therapy	No ICU admission/ recovered	16
4/ 33 years/Not reported	2 SS, one /Sβ ⁰ -thalassemia and one SC/Not reported	One ICU admitted/all recovered	17
83/30 years /Not reported	85.5%SS/Sβ ⁰ - thalassemia, 9.5% SC, 5% Sβ ⁺ /46%	20% - 2 SC patients/No increased risk of morbidity and mortality	18
1 / 45 years/Not reported	SS/ on HU therapy	-/recovered	19
9/27.9 years/1.5-30.4%	8 SS, one SC/67% on HU therapy	One ICU admitted/all recovered	20
10/36 years/Not reported	9 SS or Sβ ⁰ -thalassemia, one SC/Not reported	No ICU admission-one death/9 recovered	21
10/40 years/6.2%	SS/ 20%	No ICU admission-one death/ mild clinical symptoms	22
67/20->59/ Not reported	Not reported/Not reported	Not reported/ 7 deaths	13
2/22 years/Not reported	SS/Not reported	No ICU admission/ both recovered	23
3/30 years/Not reported	SS/all on HU therapy	No ICU admission/ all recovered	24
1/44 years/ Not reported	Not reported	No ICU admission/ recovered	25
Two adults and one child/27.3 years/Not reported	SS/None	-/Mild/ 2 non-pneumonic	27
6/30 years/ Not reported	Not reported/ Not reported	No ICU admission/all recovered	28
22 years/Not reported	SS/ Not reported	No ICU admission/mild/recovered	29
252>19 years/Not reported	Not reported/ Not reported	-/16 deaths (6.3%)	14

SCD: Sickle cell disease; HU: hydroxyurea; COVID-19: Coronavirus disease 2019 (COVID-19); ICU: Intensive care unit; SS: sickle cell homozygous